Top Industry News

Vertex Pharmaceuticals has agreed to acquire Crinetics Pharmaceuticals, a San Diego, California-based bio/pharmaceutical company focused on endocrine diseases, for $10 billion.  Crinetics’ marketed medicine is Palsonify (paltusotine), a once-daily oral therapy for adults with acromegaly, a rare condition caused by a…

Novartis has agreed to acquire Myricx Bio, a privately held London-based bio/pharmaceutical company developing antibody-drug conjugates (ADCs), in a deal worth up to $1.5 billion ($1.1 billion upfront and $400 million in milestone payments).   Myricx is developing ADCs using N-myristoyltransferase inhibitor (NMTi)…

Evonik has announced a $100-million investment to strengthen its active pharmaceutial ingredient manufacturing capabilities at its Tippecanoe Labs site in Lafayette, Indiana. Over the next five years, Evonik will invest $100 million to…

The latest from CDMOs, CMOs, and suppliers featuring Lonza, Olon, Bora Pharmaceuticals, Codis, Icosagen, Mikart, Thermo Fisher, Gattefosse, Just Evotec Biologics, Rentschler Biopharma and Nona Biosciences.   Chemicals/Chemical API Manufacturing * Lonza Expands HPAPI Mfg Facility* Olon Completes Expansion…

A roundup of news from the large and mid-sized bio/pharmaceutical companies featuring AstraZeneca, Sanofi, Incyte, Ispen, Teva, Boehringer Ingelheim, and Tanabe Pharma. Highlights below.   For the latest news roundup on small and…

The latest from small and Emerging Pharma companies featuring BridgeBio Pharma, MeiraGTx, Kalohexis, Biocytogen, and Whitehawk Therapeutics.   For news on the large and mid-sized bio/pharmaceutical companies, see Global Briefs.  * BridgeBio Pharma Raises Nearly $1 Bn…

In a move to bolster its life-sciences business, Merck KGaA has agreed to acquire Bio-Techne, a Minneapolis-Minnesota provider of life-science tools, analytical technologies, and consumables, for $11.3 billion. The acquisition is one of…

To boost its portfolio in inflammatory and immunological therapeutics, AbbVie has agreed to acquire Apogee Therapeutics, a Waltham, Massachusetts-based clinical-stage bio/pharmaceutical company, for $10.9 billion.  Apogee’s lead assets are zumilokibart, a subcutaneous half-life extended monoclonal antibody for treating atopic dermatitis (eczema) in Phase…

Sanofi has named Paulo Fontoura, MD, PhD, an ex-Roche executive and currently Chief Medical Officer at Xaira Therapeutics, a South San Francisco, California-based company focused on applying AI and machine learning in drug discovery and development, as Executive Vice President,…

The latest from CDMOs, CMOs, and suppliers featuring Siegfried, Evonik, Aurobindo, Alcami, Sartorius, SK pharmteco, Shilpa Biologicals, Minaris, Argonaut Manufacturing Services, and Ensera.   Chemicals/Chemical API Manufacturing * Siegfried Opens Large-Scale API Facility* Evonik Divests Select Pharma Ingredient Production…